Self-Reported Medication Adherence Measured with Morisky Scales in Rare Disease Patients: A Systematic Review and Meta-Analysis

Author:

García-Muñoz Ana María1ORCID,Victoria-Montesinos Desirée1ORCID,Cerdá Begoña1ORCID,Ballester Pura1ORCID,de Velasco Eloisa María1,Zafrilla Pilar1ORCID

Affiliation:

1. Faculty of Pharmacy and Nutrition, Universidad Católica San Antonio de Murcia (UCAM), Campus de los Jerónimos, 30107 Murcia, Spain

Abstract

Background: The visibility of Rare Diseases is a new challenge for society. These diseases are numerous, heterogeneous in nature and distribution, characterized by a high mortality rate but low prevalence, and usually presenting a severe evolution. Adherence to medication studies in rare diseases are uncommon, due to treatment scarcity. Objectives: The main purpose of this study is to do a meta-analysis, evaluating the level of adherence to medication in the most prevalent rare diseases. Methods: This work is a systematic review, and meta-analysis was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (Registration number: CRD42022372843) and conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Adherence to treatment in this systematic review and meta-analysis was collected from all studies included, based on the crude numerators and denominators reported, using either the Morisky Medication Adherence Scale 4 or -8. Results: A total of 54 records were identified through database searches, or after screening relevant manuscripts’ references. Finally, 18 studies were included in this systematic review and meta-analysis. A total of 1559 participants (54.18% women) aged less than 84 years old were included. Twelve studies used the MMAS-8. In 8 of them, they established the level of adherence to treatment in three categories (low, medium, and high), with the mean prevalence in each of them being 41.4%, 30.4%, and 28.2%, respectively. Conclusions: The results observed in adherence to treatment in patients with rare diseases show great variability, due to the different aspects involved in the greater or lesser applicability of the medication.

Publisher

MDPI AG

Subject

Health Information Management,Health Informatics,Health Policy,Leadership and Management

Reference66 articles.

1. Belzer, L.T., Wright, S.M., Goodwin, E.J., Singh, M.N., and Carter, B.S. (2022). Psychosocial Considerations for the Child with Rare Disease: A Review with Recommendations and Calls to Action. Children, 9.

2. Collin-Histed, T., Gershkowitz, J., Stevens, B., and Timmins, G. (2022). Lysosomal Storage Disorders, John Wiley & Sons, Ltd.

3. Estimating Cumulative Point Prevalence of Rare Diseases: Analysis of the Orphanet Database;Lambert;Eur. J. Hum. Genet.,2020

4. EURODIS (2022, December 19). What Is a Rare Disease?. Available online: https://www.eurordis.org/information-support/what-is-a-rare-disease/.

5. Hedley, V., Hannah, M., Charlotte, R., and Ségolène, A. (2018). Report on the State of the Art of Rare Disease Activities in Europe, European Commission.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3